Cannabinoids Anti Cancer Mechanism Potential | cannabisMD

Cannabinoids Anti Cancer Mechanism Potential

Anti cancer potential in cannabinoids

Cannabinoids are a group of chemical compounds that are situated in the the marijuana plant. The cannabis plant (cannabis sativa) hosts two main cannabinoids and these are tetrahydrocannabinol (THC) and cannabidiol (CBD). THC is the main psychoactive part of cannabis and is said to give off a ‘stoned feeling’ when it is induced in animals. CBD is said to hold anti inflammatory mechanisms to treat a whole range of human disorders. Cannabinoids have the main receptors in the bodies endocannabinoid system that allows cannabinoids to carry out their duties. Cancer is a group of disorders involving non natural cell development with the plausibility to invade or grow in other regions of the body. These contrast with malignant tumors, which do not grow in other parts of the body. Possible symptoms of cancer include a lump, non natural bleeding, durated cough, unknown weight loss and increased bowel motility. While these signs might suggest cancer is imminent, they may have other causes. Over 100 different sorts of cancer have effects on humans. This paper will look at cannabinoids and their anticancer mechanisms.

Here is the full scientific article if you wish to download it.

Main Points

  • Cannabinoids as potential anticancer agents?
  • Therapeutic value of cannabinoids in cancer

Cannabinoids as potential anticancer agents?

More so to the well-known palliative impacts of cannabinoids on some cancer-related conditions, a large body of fingers point at the suggestion that these atoms can reduce tumour development in animal models of cancer. They do so by changing key cell transmissioning pathways in cahoots with the mediation of cancer cell proliferation and survival. More so, cannabinoids induce angiogenesis and reduce metastasis in different tumour types in laboratory animals. In this study, the researchers flirt with the most recent understanding of cannabinoids as antitumour drugs, highlighting on recent findings about their molecular mechanisms of action, including blockade actions and chances for their application in combination therapy. Those findings have already lended a hand to the basis for the growth of larval clinical research that will analyze the security and plausibility clinical benefit of cannabinoids as anticancer drugs.

Therapeutic value of cannabinoids in cancer

With regard to patient stratification, the specific ones that are possibly responsive to cannabinoid dosing should be unequivocally deemed. To that extent, high-throughput methods should be put in place to discover cannabinoid therapy–related biomarkers in tumour biopsies or, more comfortably, in easily gained fluids baring circulating cancer cells or increased levels of resistance factors that may have been opened by cancer cells. Such biomarkers would conceivably be associated with cannabinoid pharmacodynamics—namely, communication and activity of cannabinoid receptors and their downstream cell-death-inhibiting effectors. The method would be analogous to the biochemical review of estrogen and ErbB2 receptors, which respectively foresee benefit from endocrine treatments and trastuzumab in breast cancer.

Jonathan Neilly
Jonathan Neilly
Jonathan Neilly is registered with the British Psychological Society, breaking the taboo on mental health issues is one of the driving forces in his life. His background in biomedicine gives him additional understanding of the factors that work together to influence the human condition.

Leave a Reply

Your email address will not be published. Required fields are marked *